| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00432-004-0620-5 |
| P698 | PubMed publication ID | 15565458 |
| P50 | author | Jochen Tuettenberg | Q39904320 |
| P2093 | author name string | Frederik Wenz | |
| Peter Vajkoczy | |||
| Rainer Grobholz | |||
| Tobias Korn | |||
| Ralf Erber | |||
| P2860 | cites work | Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity | Q24561642 |
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality | Q28166312 | ||
| Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene | Q28202069 | ||
| Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer | Q28376841 | ||
| Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria | Q29616614 | ||
| Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group | Q30584392 | ||
| Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse | Q30647642 | ||
| Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis | Q33178917 | ||
| Phase I trial of temozolomide using an extended continuous oral schedule. | Q33503863 | ||
| Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation | Q33868831 | ||
| Antiangiogenic therapy in brain tumor models | Q33938969 | ||
| Redefining the target: chemotherapeutics as antiangiogenics | Q34142103 | ||
| Antiangiogenic scheduling of lower dose cancer chemotherapy. | Q34427979 | ||
| Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis | Q35148959 | ||
| Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma | Q35208736 | ||
| Inhibition of angiogenesis by non-toxic doses of temozolomide | Q35213979 | ||
| Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2 | Q36369190 | ||
| A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse | Q36621800 | ||
| Antiangiogenic potential of camptothecin and topotecan | Q39518724 | ||
| Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. | Q40657509 | ||
| Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy | Q40753323 | ||
| Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal | Q40848490 | ||
| Angiogenesis in malignant gliomas | Q40961541 | ||
| Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing | Q41705080 | ||
| SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. | Q41756065 | ||
| NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. | Q43726776 | ||
| Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. | Q43770323 | ||
| Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts | Q43860650 | ||
| Fatal allergic vasculitis associated with celecoxib | Q43919660 | ||
| Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase | Q43961971 | ||
| SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice | Q43972645 | ||
| Placental growth factor is a survival factor for tumor endothelial cells and macrophages | Q43998967 | ||
| Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma | Q44115238 | ||
| Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. | Q44235692 | ||
| COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy: reports from a symposium held in conjunction with the Radiation Therapy Oncology Group June 2001 Meeting | Q44539559 | ||
| Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors | Q45308366 | ||
| Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. | Q45875779 | ||
| Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo | Q48114757 | ||
| Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials | Q48286137 | ||
| Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. | Q48789795 | ||
| Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. | Q53970403 | ||
| Microvessel density is a prognostic indicator for patients with astroglial brain tumors. | Q55479921 | ||
| Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme | Q55489464 | ||
| Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease | Q67900636 | ||
| Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene | Q68977946 | ||
| Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents | Q73441683 | ||
| Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors | Q73574321 | ||
| Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines | Q73803470 | ||
| Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma | Q73840540 | ||
| Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody | Q74802802 | ||
| Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic | Q77683561 | ||
| P433 | issue | 1 | |
| P921 | main subject | glioblastoma | Q282142 |
| angiogenesis inhibitor | Q574834 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 31-40 | |
| P577 | publication date | 2004-09-28 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme | |
| P478 | volume | 131 |
| Q38409615 | Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro |
| Q37504362 | Angiogenesis as a therapeutic target in malignant gliomas |
| Q42732588 | Antiangiogenesis in recurrent glioblastoma: proof of principle |
| Q37533652 | Antiangiogenic strategies for treatment of malignant gliomas |
| Q38157034 | Antiangiogenic therapy for high-grade gliomas: current concepts and limitations |
| Q43197450 | Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. |
| Q64994045 | Biomarkers for glioblastoma multiforme: status quo. |
| Q35027024 | Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme |
| Q43072513 | Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma |
| Q38662901 | Critical Care Management of Cerebral Edema in Brain Tumors |
| Q46817843 | Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma |
| Q38969912 | Cyclooxygenase-2 in glioblastoma multiforme |
| Q36779651 | Emerging treatments and gene expression profiling in high-risk medulloblastoma |
| Q38943301 | Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells |
| Q34127138 | Experimental approaches for the treatment of malignant gliomas |
| Q48794947 | Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme |
| Q33543830 | Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib |
| Q37575528 | Insights into pharmacotherapy of malignant glioma in adults |
| Q35895174 | Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. |
| Q64071354 | Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience |
| Q38087885 | Metronomic chemotherapy for cancer treatment: a decade of clinical studies |
| Q40867629 | Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis |
| Q43196861 | Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth |
| Q33644407 | Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies |
| Q36409038 | Multi-functional polymeric nanoparticles for tumour-targeted drug delivery |
| Q36200166 | Novel advances in drug delivery to brain cancer |
| Q46362575 | Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. |
| Q30441458 | Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. |
| Q35008766 | Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy |
| Q33388306 | Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma |
| Q47110281 | Postoperative extracranial metastasis from glioblastoma: a case report and review of the literature |
| Q33384898 | Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma |
| Q37400645 | Rechallenge with temozolomide in patients with recurrent gliomas |
| Q46092458 | Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. |
| Q39218093 | Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib |
| Q35177942 | Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review |
| Q37995906 | Temozolomide dosing regimens for glioma patients |
| Q37078957 | The emerging role of anti-angiogenic therapy for malignant glioma |
| Q39489252 | The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway |
| Q26825502 | The role of NF-κB in the pathogenesis of glioma |
| Q42116284 | The use of Cox-2 and PPARγ signaling in anti-cancer therapies |
| Q37708428 | Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience |
| Q35922107 | Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma |
Search more.